- Home
- CDXS vs SLS Comparison
CDXS vs SLS Comparison
Compare CDXS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- SLS
- Stock Information
- Founded
- CDXS 2002
- SLS 2012
- Country
- CDXS United States
- SLS United States
- Employees
- CDXS N/A
- SLS N/A
- Industry
- CDXS Major Chemicals
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- SLS Health Care
- Exchange
- CDXS Nasdaq
- SLS Nasdaq
- Market Cap
- CDXS 201.3M
- SLS 169.6M
- IPO Year
- CDXS 2010
- SLS N/A
- Fundamental
- Price
- CDXS $2.27
- SLS $1.54
- Analyst Decision
- CDXS Buy
- SLS
- Analyst Count
- CDXS 2
- SLS 0
- Target Price
- CDXS $11.00
- SLS N/A
- AVG Volume (30 Days)
- CDXS 1.0M
- SLS 2.5M
- Earning Date
- CDXS 08-07-2025
- SLS 08-12-2025
- Dividend Yield
- CDXS N/A
- SLS N/A
- EPS Growth
- CDXS N/A
- SLS N/A
- EPS
- CDXS N/A
- SLS N/A
- Revenue
- CDXS $49,815,000.00
- SLS N/A
- Revenue This Year
- CDXS $12.77
- SLS N/A
- Revenue Next Year
- CDXS $22.12
- SLS N/A
- P/E Ratio
- CDXS N/A
- SLS N/A
- Revenue Growth
- CDXS N/A
- SLS N/A
- 52 Week Low
- CDXS $1.90
- SLS $0.77
- 52 Week High
- CDXS $6.08
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- CDXS 48.16
- SLS 45.96
- Support Level
- CDXS $2.20
- SLS $1.47
- Resistance Level
- CDXS $2.51
- SLS $1.73
- Average True Range (ATR)
- CDXS 0.14
- SLS 0.11
- MACD
- CDXS -0.00
- SLS -0.02
- Stochastic Oscillator
- CDXS 42.65
- SLS 19.44
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.